[Chronic hepatitis C: what to do if the first treatment failed?].
Asselah
Tarik
T
Service d'Hépatologie, INSERM U481, Centre de Recherche Claude-Bernard sur les Hépatites Virales, Hôpital Beaujon, 92118 Clichy.
D000547:Amantadine / Q000008:administration & dosage / Q000627:therapeutic use; D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000209:etiology / Q000517:prevention & control; D004359:Drug Therapy, Combination; D000431:Ethanol / Q000009:adverse effects; D005500:Follow-Up Studies; D019698:Hepatitis C, Chronic / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D007372:Interferons / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000209:etiology; D008113:Liver Neoplasms / Q000209:etiology / Q000517:prevention & control; D051379:Mice; D008822:Mice, Transgenic; D015337:Multicenter Studies as Topic; D009765:Obesity / Q000150:complications; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects; D013997:Time Factors
D000998:Antiviral Agents; D000431:Ethanol; D012254:Ribavirin; D007372:Interferons; D000547:Amantadine